Lengthy, antimicrobial therapy targeting the pathogen is the mainstay of conventional tuberculosis treatment, complicated by emerging drug resistances. We have been working on Host-directed therapies, mainly in non-steroidal anti-inflammatory drugs (NSAIDs), since 2010. In collaboration with our colleagues from the University Medical Center Groningen and the HDT-Network, we have just published in Frontiers Immunology Journal a Systematic Review in which investigate whether NSAIDs display any effects as therapy of TB. We have included ten studies, seven preclinical studies in mice and three clinical trials. Our results point toward a beneficial effect of NSAIDs as adjunct to current TB therapy regimens, even if the determination of the best timing for their administration needs further investigation.
You can read and download the paper here.